[1]王静,王成,张春妮.血清miR-25和miR-100作为食管鳞状细胞癌诊断和预后标志物研究[J].现代检验医学杂志,2015,30(05):17-21.[doi:10.3969/j.issn.1671-7414.2015.05.006]
　WANG Jing,WANG Cheng,ZHANG Chun-ni.Study on Serum miR-25 and miR-100 as Diagnostic and Prognostic Markers for Esophageal Squamous Cell Carcinoma[J].Journal of Modern Laboratory Medicine,2015,30(05):17-21.[doi:10.3969/j.issn.1671-7414.2015.05.006]
点击复制

血清miR-25和miR-100作为食管鳞状细胞癌诊断和预后标志物研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第30卷
期数:
2015年05期
页码:
17-21
栏目:
论著
出版日期:
2015-12-10

文章信息/Info

Title:
Study on Serum miR-25 and miR-100 as Diagnostic and Prognostic Markers for Esophageal Squamous Cell Carcinoma
作者:
王静; 王成; 张春妮
南京军区南京总医院检验科，南京210002
Author(s):
WANG Jing; WANG Cheng; ZHANG Chun-ni
Department of Clinical Laboratory， Nanjing General Hospital of Nanjing Military Command，Nanjing 210002，China
关键词:
食管鳞状细胞癌; miR-25; miR-100; 诊断; 预后
分类号:
R735.1；R730.43
DOI:
10.3969/j.issn.1671-7414.2015.05.006
文献标志码:
A
摘要:
目的探讨血清miR-25和miR-100对食管鳞状细胞癌(esophageal squamous cell carcinoma，ESCC)的诊断和预后价值。方法收集2011年6月～2014年5月南京军区南京总医院及徐州市肿瘤医院63例ESCC患者术前、术后及随访血清，并收集63例年龄、性别匹配的非癌健康人血清作为对照；实时荧光定量PCR法检测血清miR-25和miR-100含量。用非参数Mann-Whitney U检验ESCC患者组和对照组血清miR-25和miR-100表达水平的差异，配对t检验分析ESCC患者术前术后血清中miR-25和miR-100的表达量变化，受试者工作特征曲线(ROC)评估血清miR-25和miR-100对ESCC的诊断价值，单因素Kaplan-Meier法分析对ESCC患者生存的影响。结果与健康对照相比，ESCC患者血清miR-25(0.40 ± 0.20 vs 0.02 ± 0.01)和miR-100的相对含量(0.10±0.02 vs 0.04±0.00)显著升高，差异具有统计学意义(U值分别为885.0和1 006.0，P值均<0.01)；血清miR-25和miR-100 的ROC曲线下面积AUC均明显大于癌胚抗原；ESCC患者术后血清miR-100含量较术前明显降低(0.07±0.01 vs 0.10±0.02)，差异具有统计学意义(t=2.367，P=0.021)；单因素Kaplan-Meier法分析显示血清miR-25和miR-100表达阴性的ESCC患者的生存期明显高于阳性患者(P<0.05)。结论血清miR-25和miR-100可作为ESCC诊断及预后评估的潜在标志物。
Abstract:
ObjectiveTo investigate the diagnostic and prognostic values of serum miR-25 and miR-100 for esophageal squamous cell carcinoma(ESCC)．MethodsSerum samples were collected from 63 ESCC patients before and after surgery in Nanjing General Hospital and Xuzhou Cancer Hospital between June 2013 and May 2014．In the meanwhile，serum samples were collected from 63 age- and sex-matched individuals as non-cancer controls．Quantitative real-time PCR was used to detect the serum concentrations of miR-25 and miR-100．The nonparametric Mann-Whitney U-test was used to analyze the differences of miR-25 or miR-100 levels between ESCC patients and controls．Paired t test was used to analyze the differences of serum miR-25 or miR-100 levels of pre-or postoperative ESCC patients．ROC curve analysis was conducted to evaluate the diagnostic value of serum miR-25 and miR-100 for ESCC． Univariate Kaplan-Meier analysis was applied to assess the prognostic value of serum miR-25 and miR-100 on the survival of patients with ESCC．ResultsCompared with controls，serum levels of miR-25 and miR-100 in ESCC patients were significantly increased (0.40±0.20 vs 0.02±0.01，U=885.0，P<0.01；0.10±0.02 vs 0.04±0.00，U=1　006，P<0.01，respectively)．ROC curve analysis showed that the areas under the ROC curves of serum miR-25 and miR-100 for ESCC were larger than that of carcinoembryonic antigen．Serum miR-100 was significantly declined in postoperative ESCC patients as compared to preoperative patients (0.07±0.01 vs 0.10±0.02，t=2.367，P=0.021)．Univariate Kaplan-Meier analysis showed that ESCC patients with low levels of miR-25 and miR-100 in their serum exhibited higher survival rates than those with high levels．ConclusionSerum miR-25 and miR-100 could be used as potential diagnostic and prognostic markers of ESCC．

参考文献/References:

［1］Ward DG，Suggett N，Cheng Y，et al．Identification of serum biomarkers for colon cancer by proteomic analysis［J］．Br J Cancer，2006，94(12)：1898-1905．
[2]Graves P，Zeng Y．Biogenesis of mammalian microRNAs：a global view［J］．Genomics Proteomics Bioinformatics，2012，10(5)：239-245．
[3]Price C，Chen J．MicroRNAs in cancer biology and therapy：current status and perspectives［J］．Genes Dis，2014，1(1)：53-63．
[4]Chen X，Ba Y，Ma L，et al．Characterization of microRNAs in serum：a novel class of biomarkers for diagnosis of cancer and other diseases［J］．Cell Res，2008，18(10)：997-1006．
[5]Liu R，Zhang C，Hu Z，et al．A five-microRNA signature identifies from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis［J］．Eur J Cancer，2011，47(5)：784-791．
[6]Chen X，Liang H，Guan D，et al．A combination of let-7d，let-7g and let-7i serves as a stable reference for normalization of serum microRNAs［J］．PLoS One，2013，8(11)：e79652．
[7]Heneghan HM，Miller N，Lowery AJ，et al．Circulating microRNAs as novel minimally invasive biomarkers for breast cancer［J］．Ann Surg，2010，251(3)：499-505．
[8]王成，张春妮．微小核糖核酸对食管癌的研究进展［J］．医学研究生学报，2011，24(6)：646-650． Wang C，Zhang CN．Research progress about micro-RNAs and its potential use for the detection，diagnosis，therapy and prognosis of esophageal cancer［J］．Journal of Medical Postgraduates，2011，24(6)：646-650．
[9]Xu X，Chen Z，Zhao X，et al．MicroRNA-25 promotes cell migration and invasion in esophageal squamous cell carcinoma［J］．Biochem Biophys Res Commun，2012，421(4)：640-645．
[10]Guo Y，Chen Z，Zhang L，et al．Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma［J］．Cancer Res，2008，68(1)：26-33．
[11]Sun J， Chen Z， Tan X，et al．MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma［J］．Med Oncol，2013，30(1)：411． 收稿日期：2015-05-05 修回日期：2015-06-02(上接16页) Huang K，Huang SL，Pan JX，et al．Protection of he-matopoietic stem cells by MIP-1α and PF4 against the cytotoxicity of chemotherapeutic［J］．Chin J Hematol，2000，21(7)：355-358．
[13]Abu El-Asrar AM，Mohammad G，Nawaz MI，et al．The Chemokine platelet factor-4 variant (PF-4var)/CXCL4L1 inhibits diabetes-induced blood-retinal barrier breakdown［J］．Invest Ophthalmol Vis Sci，2015，56(3)：1956-1964．
[14]Gupta SK，Hassel T，Singh JP．A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4［J］．Proc Natl Acad Sci USA，1995，92(7)：7799-7803．
[15]Li XK，Jiang LJ，Wang Y，et al．Inhibition of angiogenesis by a novel small peptide consisting of the active fragments of platelet factor-4 and vasostatin［J］．Cancer Letters，2007，256(1)：29-32．
[16]Sandset PM．CXCL4-platelet factor 4，heparin-induced thrombocytopenia and cancer［J］．Thrombosis Research，2012，129(Suppl 1)：S97-S100．
[17]Kowalska MA，Rauova L，Poncz M．Role of the pla-telet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis［J］．Thrombosis Research，2010，125(4)：292-296．
[18]王红梅，田晶晶，段生宝，等．肝素诱导血小板减少症抗体的酶联免疫吸附检测方法研究［J］．现代检验医学杂志，2014，29(6)：65-68． Wang HM，Tian JJ，Duan SB，et al．Application of ELISA in detecting heparin-induced thrombocytopenia antibodies［J］．J Mod Lab Med，2014，29(6)：65-68．
[19]Pilatova1 K，Greplova K，Demlova R，et al．Role of platelet chemokines，PF-4 and CTAP-III，in cancer biology［J］．Journal of Hematology & Oncology，2013(6)：42．
[20]Peterson JE，Zurakowski D，Italiano JE，et al．VE-GF，PF4 and PDGF are elevated in platelets of colorectal cancer patients［J］．Angiogenesis，2012，15(2)：265-273．
[21]康虹阳，邵会媛，张伶．血小板第4因子的抗肿瘤发生机制及其生物学检测［J］．生命的化学，2010，30(2)：318-321． Kang HY，Shao HY，Zhang L．The tumor regulating mechanism and the detection of PF4［J］．Chemistry of Life，2010，30(2)：318-321．
[22]Maione TE，Gray GS，Petro J，et al．Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides［J］．Science，1990，247(4938)：77-79．
[23]Lippi G，Favaloro EJ．Recombinant platelet factor 4：A therapeutic，anti-neoplastic chimera［J］．Semin Thromb Hemost，2010，36(5)：558-569．

相似文献/References:

[1]李陕区a,兰 淼b,赵仁礼,等.蛋白酪氨酸磷酸酶受体D(PTPRD)在食管鳞状细胞癌组织中的表达及其临床意义[J].现代检验医学杂志,2016,31(01):1.[doi:10.3969/j.issn.1671-7414.2016.01.001]
　LI Shan-qua,LAN Miaob,ZHAO Ren-li,et al.Expression and Clinical Relations of PTPRD in Esophageal Squamous Cell Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(05):1.[doi:10.3969/j.issn.1671-7414.2016.01.001]
[2]和新盈,王书文,李 宇,等.miR-25靶向作用FBXO33在肾透明细胞癌凋亡及预后的相关实验研究[J].现代检验医学杂志,2017,32(01):38.[doi:10.3969/j.issn.1671-7414.2017.01.011]
　HE Xin-ying,WANG Shu-wen,LI Yu,et al.Study on the Relationship of MiR-25 Targeting FBXO33 with Cell Apoptosis and Prognosis in Renal Cell Carcinoma[J].Journal of Modern Laboratory Medicine,2017,32(05):38.[doi:10.3969/j.issn.1671-7414.2017.01.011]
[3]贾亚旭,王 成,张春妮.血清miR-193a-3p,miR-337-5p和miR-483-5p在食管鳞状细胞癌诊断和预后中的应用[J].现代检验医学杂志,2017,32(02):5.[doi:10.3969/j.issn.1671-7414.2017.02.002]
　JIA Ya-xu,WANG Cheng,ZHANG Chun-ni.Application of Serum miR-193a-3p,miR-337-5p and miR-483-5p in the Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma[J].Journal of Modern Laboratory Medicine,2017,32(05):5.[doi:10.3969/j.issn.1671-7414.2017.02.002]
[4]徐　超,徐　珊,窦 　燕,等.食管鳞状细胞癌组织PTOV1，IGBP1的表达与临床病理特征和预后相关性研究[J].现代检验医学杂志,2022,37(03):100.[doi:10.3969/j.issn.1671-7414.2022.03.021]
[5]李智军a,姜海燕b,边 超a,等.LINC01503 调控ERK 磷酸化促进食管鳞状细胞癌放疗抵抗的机制研究[J].现代检验医学杂志,2023,38(02):25.[doi:10.3969/j.issn.1671-7414.2023.02.005 ]
　LI Zhi-juna,JIANG Hai-yanb,BIAN Chaoa,et al.Mechanism of LINC01503 Promotes Radiotherapy Resistance to Esophageal Squamous Cell Carcinoma by Regulating ERK Phosphate Acidization[J].Journal of Modern Laboratory Medicine,2023,38(05):25.[doi:10.3969/j.issn.1671-7414.2023.02.005 ]

备注/Memo

备注/Memo:
基金项目：国家自然科学基金资助项目(81171661)。 作者简介：王静(1983-)，女，本科，技师，从事临床医学检验工作，E-mail：wjing0605@sina.com。 通讯作者：张春妮(1963-)，女，博士，主任技师，博士生导师，主要研究方向：临床检验诊断学，E-mail：zchunni27@hotmail.com。
更新日期/Last Update: 1900-01-01